Unipolar Depression Clinical Trial
Official title:
Thinking Healthy Program - Peer Delivered in Pakistan
The rates of perinatal depression in South Asian women are reported to be amongst the highest in the world, ranging from 18%-30% in urban areas and 28%-36% in rural areas. In addition to its profound impact on women's health, disability and functioning, perinatal depression is associated with poor child health outcomes such as pre-term birth, infant under-nutrition and stunting. There is robust evidence that perinatal depression can be effectively managed with psychological treatments delivered by non-specialist health care workers. Our previous research conducted in Pakistan led to the development of the Thinking Healthy Program (THP). THP is a psychological treatment delivered by community health workers (CHWs) which more than halved the rate of perinatal depression among mothers and led to significant improvements in child health outcomes. To enhance access to such evidence-based psychological treatments, there is a need to examine the potential role of other human resources such as lay persons in delivering psychological treatments such as THP in poor resource settings.
Objectives To evaluate the effectiveness and cost-effectiveness of THP delivered by peers
(the Thinking Healthy Program - Peer delivered in Rawalpindi, Pakistan; THPP-P) over the
duration of 6 months. Peers will be healthy mothers who live in the same community as
potential trial participants (TPs).
Study design and outcomes Single-blind stratified cluster randomized controlled trial in
Rawalpindi, Pakistan (rural area) involving 40 clusters (560 women). TPs will not be blinded
to treatment allocation. TPs include all pregnant women in their third trimester of pregnancy
who are identified through the list of their local community health worker (Lady Health
Worker or LHW). Those who are eligible will be invited to participate in screening for
depression; mothers who consent will be screened for depression with a locally validated
version of the Patient Health Questionnaire (PHQ-9). TPs who screen positive (PHQ-9 score ≥
10) receive enhanced usual care (EUC) or THPP+EUC. The primary outcome measures will be
remission (i.e. recovery from depression) and reduction in depressive symptoms, both assessed
by the PHQ-9 at 6 months post child birth. Secondary outcomes are depressive symptoms and
remission at 3 months (PHQ-9), maternal disability at 3 and 6 months post child birth
(measured with the WHO-DAS), improved maternal support (measured with MSPSS) at 3 and 6
months post child birth, breastfeeding rates and infant weight and height of children at 3
and 6 months. Outcomes will be analysed on an intention to treat basis.
Interventions EUC will comprise communicating the results to the mother's LHW and medical
officer (MO) at the Basic Health Unit (BHU) of her area, providing the MO with the WHO mhGAP
guidelines for the treatment of depression, and providing guidance on referral of depressed
mothers to mental health services. TPs who are in the THPP group will receive, in addition,
14 sessions of THPP starting from their recruitment in the third trimester until up to 5
months after child birth. Sessions will be delivered by peers on an individual and group
basis at a location of convenience to the TPs (usually at their own homes).
Implications THPP has the potential to advance knowledge of the extent to which task-shifting
of the delivery of evidence-based psychological treatments can be extended to peers in the
community. If effectiveness is observed, this approach offers a potential opportunity to
access a vast untapped human resource for maternal mental health care and addresses a major
barrier in global mental health - the lack of skilled and motivated human resources in the
formal health sector - offering a new avenue for the scaling up of evidence-based
psychological treatments in low resourced settings.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03256162 -
Ketamine as an Adjunctive Therapy for Major Depression
|
Phase 1 | |
Recruiting |
NCT05570110 -
Enoxolone in Major Depression - Biomarker-outcome Relationship
|
Phase 1/Phase 2 | |
Completed |
NCT02530164 -
Transcranial Direct Current Stimulation (tDCS) As Treatment for Major Depression
|
N/A | |
Completed |
NCT00964054 -
Depression Outcomes Study of Exercise
|
Phase 1 | |
Completed |
NCT01447602 -
A Clinical Trial of IPT-A to Prevent Suicide in Depressed Adolescents With Suicidal Behavior
|
Phase 3 | |
Completed |
NCT00517387 -
The Effects of Quetiapine XR on Cognition, Mood and Anxiety Symptoms in SSRI-Resistant Unipolar Depression
|
Phase 3 | |
Recruiting |
NCT04939649 -
Ketamine as an Adjunctive Therapy for Major Depression (2)
|
Phase 3 | |
Recruiting |
NCT05894980 -
How to Reduce Suicidal Thoughts and Impulsivity in Depression
|
N/A | |
Terminated |
NCT04712968 -
Efficacy of Daylight as Adjunctive Treatment in Patients With Depression
|
N/A | |
Enrolling by invitation |
NCT04717921 -
Assesment of Retinal Nerve Fiber Layer in First Episode Depressive Patients Using Selective Serotonin Reuptake Inhibitor
|
||
Recruiting |
NCT03358056 -
Effects of Mindfulness Based Cognitive Therapy on Emotional Processing
|
N/A | |
Recruiting |
NCT03711019 -
Efficacy of Convulsive Therapies During Continuation
|
N/A | |
Completed |
NCT02104232 -
Thinking Healthy Program - Peer Delivered, India (THPP-I)
|
N/A | |
Terminated |
NCT01219686 -
EScitalopram PIndolol ONset of Action
|
Phase 2/Phase 3 | |
Completed |
NCT00158990 -
Triiodothyronine (T3) Supplementation in the Treatment of Bipolar and Unipolar Depression.
|
Phase 3 | |
Completed |
NCT01049347 -
Amitriptyline and Paroxetine Treatment of Major Depression
|
Phase 3 | |
Completed |
NCT03268434 -
Evaluation of Metacognitive Training for Depression (D-MCT) in Outpatient Care
|
N/A | |
Completed |
NCT01880957 -
PET and MRI Brain Imaging of Bipolar Disorder
|
N/A | |
Completed |
NCT04420793 -
Voice Changes During ECT
|
||
Not yet recruiting |
NCT01694030 -
Effects of Repeated Attachment Security Priming on Depressed Mood: a Clinical Study
|
Phase 1 |